Remarkable response to alectinib for metastatic papillary thyroid cancer with STRN-ALK fusion: A case report

Overview of attention for article published in Frontiers in oncology, November 2022

Altmetric Badge

Mentioned by

twitter: 2 X users

Readers on

mendeley: 6 Mendeley

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 25,625 followers.

Remarkable response to alectinib for metastatic papillary thyroid cancer with STRN-ALK fusion: A case report https://t.co/pJaNlTgrRS https://t.co/J5opmeyzfJ

10 Nov 2022

Reply Repost Favourite

New research: Remarkable response to alectinib for metastatic papillary thyroid cancer with STRN-ALK fusion: A case report: Little is known about the efficacy of alectinib for papillary thyroid cancer with STRN-ALK fusion. A 64-year-old female… https://t.c

09 Nov 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.